Big picture, it's very clear the company is focused on being a going concern, and expects that. That may seem overly simplistic, but i have to say that i didn't know what this call would hold. and given the collapse in the SP, the total silence in the past couple months, etc., i wondered if they were re-organizing (not in a good way, that is).

it's clear they are moving forward - and the market value is now $240MM - which again, is a value that reflects they will hit effectively none of their targets to treat any indication. that basically values them at doing about $50MM in total revenue (biotechs trade at about 5-6X revenue).

while i am as bummed out as anyone regarding the SP, and frankly the last year in general, I think buying this drug at $240MM remains a bargain (whether you hit the lows this morning or not - which i did not), so i am inclined to hold my nose and buy some more. that said, who knows if we have indeed set the lows - so i'm not going to dump all of my remaining investable funds in at once.

Good luck to all in whatever they decide to do.